Concepedia

Anke Baum

AB

Statistics

Publications

22

Citations

3.7K

H-Index

18

Active since

1989

Affiliations

Boehringer Ingelheim (Austria)(Current)

Boehringer Ingelheim (Germany)

Research Institute of Molecular Pathology

Medical University of Vienna

Anke Baum is an author at Boehringer Ingelheim (Austria) specializing in oncology, medicine, and cancer pharmacology.

ORCID

Publications per year

1989–2024

22

Publications

22

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

D Li, Lauren Ambrogio, Takeshi Shimamura et al. · Oncogene · 2008 · 1.4K citations · Full text

, , +11

BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo

Martin Steegmaier, Matthias Hoffmann, Anke Baum et al. · Current Biology · 2007 · 849 citations · Full text

, , +14

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

Dorothea Rudolph, Martin Steegmaier, Matthias Hoffmann et al. · Clinical Cancer Research · 2009 · 393 citations · Full text

, , +15

Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors

Harald Engelhardt, Dietrich Böse, Mark Petronczki et al. · Journal of Medicinal Chemistry · 2019 · 145 citations · Full text

, , +17

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases

Frank Hilberg, Ulrike Tontsch-Grunt, Anke Baum et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 105 citations · Full text

, , +17

1–5 of 22